Equivalence of MammaPrint array types in clinical trials and diagnostics.
about
Progress in the clinical detection of heterogeneity in breast cancerSelecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.A breast cancer gene signature for indolent disease.Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.An integrated lncRNA, microRNA and mRNA signature to improve prognosis prediction of colorectal cancer.
P2860
Equivalence of MammaPrint array types in clinical trials and diagnostics.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@ast
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@en
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@nl
type
label
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@ast
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@en
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@nl
prefLabel
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@ast
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@en
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@nl
P2093
P2860
P50
P1476
Equivalence of MammaPrint array types in clinical trials and diagnostics.
@en
P2093
Anke Witteveen
Arno Floore
Christa Dreezen
Diederik Wehkamp
Guido Brink
Inès Beumer
John Zheng
Laura van 't Veer
Leonie Delahaye
Mireille Snel
P2860
P2888
P304
P356
10.1007/S10549-016-3764-5
P407
P577
2016-03-22T00:00:00Z
P5875
P6179
1038901221